Loading…
A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells
Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanopa...
Saved in:
Published in: | Molecular pharmaceutics 2019-09, Vol.16 (9), p.4031-4044 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23 |
---|---|
cites | cdi_FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23 |
container_end_page | 4044 |
container_issue | 9 |
container_start_page | 4031 |
container_title | Molecular pharmaceutics |
container_volume | 16 |
creator | Younis, Mahmoud A Khalil, Ikramy A Abd Elwakil, Mahmoud M Harashima, Hideyoshi |
description | Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanoparticles (LNPs) encapsulating both the chemotherapeutic drug, sorafenib (SOR), and siRNA against the midkine gene (MK), thereby conferring a novel highly efficient anticancer effect on HCC. The LNPs were modified with a targeting peptide, SP94, which is selective for hepatic cancer cells (HCCs), thus permitting the specific delivery of the payload. MK-siRNA increased the sensitivity of HCCs, HepG2, to SOR (IC50 for SOR+MK-siRNA: 5 ± 1.50 μM compared to 9 ± 2.20 and 17 ± 2.60 μM for SOR+control siRNA and MK-siRNA, respectively). The selectivity was confirmed by cellular uptake, cytotoxicity, and gene-silencing studies in HCCs, HepG2, and Hepa 1–6, compared to other cancerous cells, HeLa, and normal cells, FL83B. The use of a novel pH-sensitive lipid, YSK05, increased the cytotoxic and gene knockdown efficiencies and limited extracellular drug release. The nanoparticles were also compatible with serum and showed no aggregation after long storage. The efficient and specific codelivery system reported here is a highly promising strategy for the treatment of HCC. |
doi_str_mv | 10.1021/acs.molpharmaceut.9b00738 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2272740566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2272740566</sourcerecordid><originalsourceid>FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23</originalsourceid><addsrcrecordid>eNqNkTFv2zAQhYkiQe2k_QsFu2WRS1KUJY6OkdQB7BRo2lk4kceariQqpGTAa355ZdgNkC3T3fC9d4f3CPnK2Ywzwb-BjrPG190WQgMah36mKsbytPhApjyTaVKkSly87oWckKsYd4wJmYn0I5mkXLK0YGJKXhZ0M9S9s0Ore-dbqOnadc4ktxDR0EdovcG900itD7TfIl25P9v6QJ861M46TZcjULs9hgP1lj75ABZbV1FoDd0489e1SKP7-bigvacr7KA_iqDVGOgS6zp-IpcW6oifz_Oa_L6_-7VcJesf3x-Wi3UCUqg-kQgclZjnymRojOJWcZ1bkVqTa2aURS444zavINVFJUHOGbJKMM4sqJG7Jjcn3y745wFjXzYu6vEDaNEPsRQiF7lk2Xw-ouqE6uBjDGjLLrgGwqHkrDxWUI4VlG8qKM8VjNov5zND1aB5Vf7PfASyE3D02PkhjKHHdxj_A10Vm9k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2272740566</pqid></control><display><type>article</type><title>A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Younis, Mahmoud A ; Khalil, Ikramy A ; Abd Elwakil, Mahmoud M ; Harashima, Hideyoshi</creator><creatorcontrib>Younis, Mahmoud A ; Khalil, Ikramy A ; Abd Elwakil, Mahmoud M ; Harashima, Hideyoshi</creatorcontrib><description>Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanoparticles (LNPs) encapsulating both the chemotherapeutic drug, sorafenib (SOR), and siRNA against the midkine gene (MK), thereby conferring a novel highly efficient anticancer effect on HCC. The LNPs were modified with a targeting peptide, SP94, which is selective for hepatic cancer cells (HCCs), thus permitting the specific delivery of the payload. MK-siRNA increased the sensitivity of HCCs, HepG2, to SOR (IC50 for SOR+MK-siRNA: 5 ± 1.50 μM compared to 9 ± 2.20 and 17 ± 2.60 μM for SOR+control siRNA and MK-siRNA, respectively). The selectivity was confirmed by cellular uptake, cytotoxicity, and gene-silencing studies in HCCs, HepG2, and Hepa 1–6, compared to other cancerous cells, HeLa, and normal cells, FL83B. The use of a novel pH-sensitive lipid, YSK05, increased the cytotoxic and gene knockdown efficiencies and limited extracellular drug release. The nanoparticles were also compatible with serum and showed no aggregation after long storage. The efficient and specific codelivery system reported here is a highly promising strategy for the treatment of HCC.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.9b00738</identifier><identifier>PMID: 31403802</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>Molecular pharmaceutics, 2019-09, Vol.16 (9), p.4031-4044</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23</citedby><cites>FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23</cites><orcidid>0000-0002-1568-9547</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31403802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Younis, Mahmoud A</creatorcontrib><creatorcontrib>Khalil, Ikramy A</creatorcontrib><creatorcontrib>Abd Elwakil, Mahmoud M</creatorcontrib><creatorcontrib>Harashima, Hideyoshi</creatorcontrib><title>A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanoparticles (LNPs) encapsulating both the chemotherapeutic drug, sorafenib (SOR), and siRNA against the midkine gene (MK), thereby conferring a novel highly efficient anticancer effect on HCC. The LNPs were modified with a targeting peptide, SP94, which is selective for hepatic cancer cells (HCCs), thus permitting the specific delivery of the payload. MK-siRNA increased the sensitivity of HCCs, HepG2, to SOR (IC50 for SOR+MK-siRNA: 5 ± 1.50 μM compared to 9 ± 2.20 and 17 ± 2.60 μM for SOR+control siRNA and MK-siRNA, respectively). The selectivity was confirmed by cellular uptake, cytotoxicity, and gene-silencing studies in HCCs, HepG2, and Hepa 1–6, compared to other cancerous cells, HeLa, and normal cells, FL83B. The use of a novel pH-sensitive lipid, YSK05, increased the cytotoxic and gene knockdown efficiencies and limited extracellular drug release. The nanoparticles were also compatible with serum and showed no aggregation after long storage. The efficient and specific codelivery system reported here is a highly promising strategy for the treatment of HCC.</description><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkTFv2zAQhYkiQe2k_QsFu2WRS1KUJY6OkdQB7BRo2lk4kceariQqpGTAa355ZdgNkC3T3fC9d4f3CPnK2Ywzwb-BjrPG190WQgMah36mKsbytPhApjyTaVKkSly87oWckKsYd4wJmYn0I5mkXLK0YGJKXhZ0M9S9s0Ore-dbqOnadc4ktxDR0EdovcG900itD7TfIl25P9v6QJ861M46TZcjULs9hgP1lj75ABZbV1FoDd0489e1SKP7-bigvacr7KA_iqDVGOgS6zp-IpcW6oifz_Oa_L6_-7VcJesf3x-Wi3UCUqg-kQgclZjnymRojOJWcZ1bkVqTa2aURS444zavINVFJUHOGbJKMM4sqJG7Jjcn3y745wFjXzYu6vEDaNEPsRQiF7lk2Xw-ouqE6uBjDGjLLrgGwqHkrDxWUI4VlG8qKM8VjNov5zND1aB5Vf7PfASyE3D02PkhjKHHdxj_A10Vm9k</recordid><startdate>20190903</startdate><enddate>20190903</enddate><creator>Younis, Mahmoud A</creator><creator>Khalil, Ikramy A</creator><creator>Abd Elwakil, Mahmoud M</creator><creator>Harashima, Hideyoshi</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1568-9547</orcidid></search><sort><creationdate>20190903</creationdate><title>A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells</title><author>Younis, Mahmoud A ; Khalil, Ikramy A ; Abd Elwakil, Mahmoud M ; Harashima, Hideyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Younis, Mahmoud A</creatorcontrib><creatorcontrib>Khalil, Ikramy A</creatorcontrib><creatorcontrib>Abd Elwakil, Mahmoud M</creatorcontrib><creatorcontrib>Harashima, Hideyoshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Younis, Mahmoud A</au><au>Khalil, Ikramy A</au><au>Abd Elwakil, Mahmoud M</au><au>Harashima, Hideyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2019-09-03</date><risdate>2019</risdate><volume>16</volume><issue>9</issue><spage>4031</spage><epage>4044</epage><pages>4031-4044</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanoparticles (LNPs) encapsulating both the chemotherapeutic drug, sorafenib (SOR), and siRNA against the midkine gene (MK), thereby conferring a novel highly efficient anticancer effect on HCC. The LNPs were modified with a targeting peptide, SP94, which is selective for hepatic cancer cells (HCCs), thus permitting the specific delivery of the payload. MK-siRNA increased the sensitivity of HCCs, HepG2, to SOR (IC50 for SOR+MK-siRNA: 5 ± 1.50 μM compared to 9 ± 2.20 and 17 ± 2.60 μM for SOR+control siRNA and MK-siRNA, respectively). The selectivity was confirmed by cellular uptake, cytotoxicity, and gene-silencing studies in HCCs, HepG2, and Hepa 1–6, compared to other cancerous cells, HeLa, and normal cells, FL83B. The use of a novel pH-sensitive lipid, YSK05, increased the cytotoxic and gene knockdown efficiencies and limited extracellular drug release. The nanoparticles were also compatible with serum and showed no aggregation after long storage. The efficient and specific codelivery system reported here is a highly promising strategy for the treatment of HCC.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31403802</pmid><doi>10.1021/acs.molpharmaceut.9b00738</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-1568-9547</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2019-09, Vol.16 (9), p.4031-4044 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_2272740566 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
title | A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A10%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Multifunctional%20Lipid-Based%20Nanodevice%20for%20the%20Highly%20Specific%20Codelivery%20of%20Sorafenib%20and%20Midkine%20siRNA%20to%20Hepatic%20Cancer%20Cells&rft.jtitle=Molecular%20pharmaceutics&rft.au=Younis,%20Mahmoud%20A&rft.date=2019-09-03&rft.volume=16&rft.issue=9&rft.spage=4031&rft.epage=4044&rft.pages=4031-4044&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.9b00738&rft_dat=%3Cproquest_cross%3E2272740566%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a429t-4ea1e92679d5edd91f91c7f23fd7c0d9fe12101f7ba3c8b4a460e0b2010fa9f23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2272740566&rft_id=info:pmid/31403802&rfr_iscdi=true |